Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lazertinib in Resectable EGFR-Mutated NSCLC
NCT05469022Phase 2Recruiting
- Sponsor
- Konkuk University Medical Center
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Konkuk University Medical Center. Primary endpoint: Objective Response Rate at 9 weeks. Started May 2022; status: recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05469022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469022.